Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops may curb worsening nearsightedness in kids

NCT ID NCT03918915

Disease control Sponsor: Sydnexis, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tested SYD-101 eye drops in 852 children with nearsightedness (myopia). The goal was to slow the worsening of vision over time. Children used the drops daily for up to 3 years. The study measured how much their eyesight changed, aiming to reduce the risk of serious eye problems later in life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

852 people

The number who actually took part.

Started

Apr 2019

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Myopia of 0.5 D (diopters) to 6.00 D (inclusive) in both eyes. * Astigmatism ≤1.50 D in both eyes. * Anisometropia ≤1.00 D in both eyes. * If myopia is ≥0.75 D, participant must be wearing single vision eyeglasses or soft, daily-wear, single-vision contact lenses that meet study investigator's criteria. * BCVA (best-corrected visual acuity) Snellen equivalent of 20/32 or better. Exclusion Criteria: * Participants with a history or current evidence of a medical condition predisposing them to degenerative myopia (e.g. Marfan syndrome, Stickler syndrome), or a condition that may affect visual function or development (e.g. diabetes mellitus, chromosome anomaly). * Current use of a monoamine oxidase inhibitor. * Evidence of any ocular inflammation or infection in either eye, including blepharitis, conjunctivitis, keratitis, and scleritis. * Past, present or future plans to use orthokeratology (orthoK), rigid gas-permeable, bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia progression; or the use of atropine, pirenzepine or other anti-muscarinic agent for myopia. * History or evidence of ocular surgery or planned future ocular surgery in either eye. Other protocol-defined inclusion/exclusion criteria could apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Near-sightedness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Near-sightedness Nearsightedness

Contacts and locations

Locations

  • Sie 136

    Bala-Cynwyd, Pennsylvania, 19004-1108, United States

  • Site 100

    Fort Collins, Colorado, 80528, United States

  • Site 101

    San Antonio, Texas, 78240, United States

  • Site 102

    Danbury, Connecticut, 06810, United States

  • Site 104

    San Diego, California, 92131, United States

  • Site 105

    Fargo, North Dakota, 58103, United States

  • Site 106

    Wilmette, Illinois, 60091, United States

  • Site 108

    Charleston, South Carolina, 29425, United States

  • Site 109

    Jupiter, Florida, 33477, United States

  • Site 110

    Santa Barbara, California, 93110, United States

  • Site 111

    Medford, Oregon, 97504, United States

  • Site 113

    Virginia Beach, Virginia, 23452, United States

  • Site 114

    Washington, Missouri, 63090, United States

  • Site 115

    The Woodlands, Texas, 77380, United States

  • Site 116

    Chicago, Illinois, 60616, United States

  • Site 117

    Chapel Hill, North Carolina, 27517, United States

  • Site 119

    Sweetwater, Florida, 33182, United States

  • Site 120

    Tamarac, Florida, 33321, United States

  • Site 121

    Raleigh, North Carolina, 27603, United States

  • Site 122

    Fort Lauderdale, Florida, 33309, United States

  • Site 123

    Boston, Massachusetts, 02111, United States

  • Site 124

    Marietta, Georgia, 30060, United States

  • Site 126

    Lakeway, Texas, 78734, United States

  • Site 127

    Buffalo, New York, 14209, United States

  • Site 128

    Cranberry Township, Pennsylvania, 16066, United States

  • Site 130

    Colorado Springs, Colorado, 80920, United States

  • Site 131

    Munster, Indiana, 46321, United States

  • Site 132

    Henderson, Nevada, 89052, United States

  • Site 133

    Sunnyvale, California, 94087, United States

  • Site 135

    Indianapolis, Indiana, 46202, United States

  • Site 137

    Pittsburg, Kansas, 66762, United States

  • Site 138

    Bangor, Maine, 04401, United States

  • Site 139

    Albuquerque, New Mexico, 87109, United States

  • Site 140

    Ogden, Utah, 84405, United States

  • Site 142

    San Antonio, Texas, 78215, United States

  • Site 143

    Irwindale, California, 91706, United States

  • Site 144

    Pasadena, California, 91105, United States

  • Site 147

    Tigard, Oregon, 97223, United States

  • Site 148

    San Diego, California, 92127, United States

  • Site 149

    Ogden, Utah, 84403, United States

  • Site 150

    Waterbury, Connecticut, 06708, United States

  • Site 200

    Trenčín, 91108, Slovakia

  • Site 201

    Trebišov, 075 01, Slovakia

  • Site 202

    Bratislava, 833 40, Slovakia

  • Site 203

    Linz, Upper Austria, 4021, Austria

  • Site 204

    Graz, Styria, 8036, Austria

  • Site 205

    Vienna, 1140, Austria